Emergent BioSolutions Inc. (NYSE:EBS) Shares Purchased by Trexquant Investment LP

Trexquant Investment LP raised its stake in Emergent BioSolutions Inc. (NYSE:EBS - Free Report) by 59.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 701,517 shares of the biopharmaceutical company's stock after buying an additional 261,099 shares during the period. Trexquant Investment LP owned about 1.29% of Emergent BioSolutions worth $6,707,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently modified their holdings of EBS. American Century Companies Inc. increased its stake in shares of Emergent BioSolutions by 23.4% during the fourth quarter. American Century Companies Inc. now owns 2,137,712 shares of the biopharmaceutical company's stock valued at $20,437,000 after buying an additional 404,667 shares during the period. State Street Corp increased its position in Emergent BioSolutions by 864.7% during the 3rd quarter. State Street Corp now owns 1,911,327 shares of the biopharmaceutical company's stock valued at $15,960,000 after purchasing an additional 1,713,200 shares during the period. Oak Hill Advisors LP bought a new stake in shares of Emergent BioSolutions in the 3rd quarter valued at about $9,296,000. Connor Clark & Lunn Investment Management Ltd. lifted its position in shares of Emergent BioSolutions by 8.3% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 902,332 shares of the biopharmaceutical company's stock worth $8,626,000 after purchasing an additional 69,157 shares during the period. Finally, Assenagon Asset Management S.A. boosted its stake in shares of Emergent BioSolutions by 3.4% during the fourth quarter. Assenagon Asset Management S.A. now owns 766,537 shares of the biopharmaceutical company's stock valued at $7,328,000 after purchasing an additional 24,985 shares in the last quarter. Hedge funds and other institutional investors own 78.40% of the company's stock.

Remove Ads

Insiders Place Their Bets

In other news, Director Neal Franklin Fowler sold 35,000 shares of the stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $5.83, for a total value of $204,050.00. Following the transaction, the director now directly owns 101,100 shares of the company's stock, valued at approximately $589,413. This represents a 25.72 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 1.20% of the company's stock.

Emergent BioSolutions Stock Up 9.3 %

Shares of EBS stock traded up $0.40 during trading hours on Wednesday, reaching $4.68. 1,338,474 shares of the company's stock were exchanged, compared to its average volume of 2,651,260. Emergent BioSolutions Inc. has a fifty-two week low of $1.82 and a fifty-two week high of $15.10. The stock's 50 day moving average is $6.78 and its 200-day moving average is $8.46. The company has a current ratio of 2.88, a quick ratio of 1.47 and a debt-to-equity ratio of 1.30. The company has a market cap of $254.30 million, a price-to-earnings ratio of -1.14 and a beta of 2.14.

Emergent BioSolutions (NYSE:EBS - Get Free Report) last released its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.05 EPS for the quarter, beating analysts' consensus estimates of ($0.35) by $0.40. Emergent BioSolutions had a negative return on equity of 9.91% and a negative net margin of 18.55%. The company had revenue of $194.70 million during the quarter, compared to analysts' expectations of $254.67 million. During the same period last year, the business posted ($0.77) earnings per share. Analysts predict that Emergent BioSolutions Inc. will post -0.63 earnings per share for the current fiscal year.

Emergent BioSolutions declared that its Board of Directors has authorized a stock buyback program on Monday, March 31st that allows the company to repurchase $50.00 million in outstanding shares. This repurchase authorization allows the biopharmaceutical company to buy up to 19% of its stock through open market purchases. Stock repurchase programs are generally an indication that the company's management believes its shares are undervalued.

Analyst Ratings Changes

A number of analysts have weighed in on the company. StockNews.com lowered Emergent BioSolutions from a "buy" rating to a "hold" rating in a report on Wednesday, March 5th. HC Wainwright restated a "buy" rating and set a $15.00 price objective on shares of Emergent BioSolutions in a research note on Tuesday, April 1st.

Emergent BioSolutions Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.